Name | Number of supported studies | Average coverage | |
---|---|---|---|
fibroblast | 26 studies | 54% ± 27% | |
smooth muscle cell | 25 studies | 50% ± 28% | |
pericyte | 25 studies | 56% ± 31% | |
astrocyte | 18 studies | 73% ± 17% | |
endothelial cell | 17 studies | 45% ± 20% | |
glutamatergic neuron | 11 studies | 52% ± 20% | |
mesothelial cell | 10 studies | 57% ± 31% | |
GABAergic neuron | 9 studies | 49% ± 18% | |
endothelial cell of lymphatic vessel | 9 studies | 53% ± 20% | |
adipocyte | 8 studies | 27% ± 13% | |
neuron | 6 studies | 32% ± 19% | |
cardiac muscle cell | 6 studies | 80% ± 15% | |
myofibroblast cell | 6 studies | 43% ± 26% | |
Mueller cell | 5 studies | 67% ± 29% | |
connective tissue cell | 5 studies | 43% ± 27% | |
type I pneumocyte | 5 studies | 70% ± 4% | |
type II pneumocyte | 5 studies | 67% ± 8% | |
epithelial cell | 4 studies | 43% ± 22% | |
macrophage | 4 studies | 22% ± 7% | |
microglial cell | 4 studies | 42% ± 25% | |
retinal ganglion cell | 4 studies | 83% ± 20% | |
muscle cell | 4 studies | 58% ± 24% | |
club cell | 4 studies | 37% ± 11% | |
interneuron | 4 studies | 48% ± 15% | |
GABAergic interneuron | 3 studies | 48% ± 5% | |
Purkinje cell | 3 studies | 79% ± 15% | |
oligodendrocyte precursor cell | 3 studies | 22% ± 5% | |
progenitor cell | 3 studies | 34% ± 15% | |
endocardial cell | 3 studies | 50% ± 22% | |
GABAergic amacrine cell | 3 studies | 31% ± 4% | |
ependymal cell | 3 studies | 80% ± 5% | |
ciliated cell | 3 studies | 21% ± 5% | |
oligodendrocyte | 3 studies | 43% ± 27% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
breast | 92% | 977.40 | 424 / 459 | 85% | 3.38 | 949 / 1118 |
lung | 100% | 2194.54 | 577 / 578 | 77% | 2.50 | 884 / 1155 |
thymus | 99% | 1422.38 | 646 / 653 | 72% | 2.72 | 438 / 605 |
intestine | 94% | 2105.11 | 910 / 966 | 71% | 2.00 | 374 / 527 |
adrenal gland | 100% | 1944.53 | 257 / 258 | 59% | 2.03 | 135 / 230 |
esophagus | 68% | 1405.49 | 981 / 1445 | 79% | 2.75 | 144 / 183 |
kidney | 72% | 488.12 | 64 / 89 | 71% | 3.46 | 639 / 901 |
bladder | 95% | 1722.67 | 20 / 21 | 47% | 1.42 | 236 / 504 |
prostate | 74% | 798.51 | 182 / 245 | 61% | 1.50 | 305 / 502 |
stomach | 55% | 760.77 | 198 / 359 | 79% | 2.76 | 225 / 286 |
uterus | 99% | 2521.44 | 169 / 170 | 34% | 1.52 | 157 / 459 |
brain | 42% | 271.10 | 1101 / 2642 | 68% | 1.54 | 476 / 705 |
ovary | 76% | 880.02 | 136 / 180 | 26% | 0.50 | 111 / 430 |
blood vessel | 100% | 9023.50 | 1335 / 1335 | 0% | 0 | 0 / 0 |
muscle | 100% | 3052.16 | 800 / 803 | 0% | 0 | 0 / 0 |
pancreas | 7% | 37.91 | 24 / 328 | 91% | 3.71 | 162 / 178 |
adipose | 97% | 1550.15 | 1165 / 1204 | 0% | 0 | 0 / 0 |
skin | 51% | 584.86 | 917 / 1809 | 44% | 1.42 | 208 / 472 |
heart | 94% | 1590.21 | 807 / 861 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 42% | 0.86 | 19 / 45 |
eye | 0% | 0 | 0 / 0 | 33% | 0.65 | 26 / 80 |
spleen | 19% | 115.28 | 45 / 241 | 0% | 0 | 0 / 0 |
liver | 2% | 12.98 | 5 / 226 | 15% | 0.30 | 62 / 406 |
lymph node | 0% | 0 | 0 / 0 | 7% | 0.09 | 2 / 29 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
peripheral blood | 0% | 0 | 0 / 929 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0019934 | Biological process | cGMP-mediated signaling |
GO_0014050 | Biological process | negative regulation of glutamate secretion |
GO_0048668 | Biological process | collateral sprouting |
GO_0061049 | Biological process | cell growth involved in cardiac muscle cell development |
GO_0010920 | Biological process | negative regulation of inositol phosphate biosynthetic process |
GO_1904706 | Biological process | negative regulation of vascular associated smooth muscle cell proliferation |
GO_2000224 | Biological process | regulation of testosterone biosynthetic process |
GO_0030900 | Biological process | forebrain development |
GO_0007165 | Biological process | signal transduction |
GO_0010737 | Biological process | protein kinase A signaling |
GO_0001764 | Biological process | neuron migration |
GO_0060087 | Biological process | relaxation of vascular associated smooth muscle |
GO_0090331 | Biological process | negative regulation of platelet aggregation |
GO_0030036 | Biological process | actin cytoskeleton organization |
GO_0007204 | Biological process | positive regulation of cytosolic calcium ion concentration |
GO_0043087 | Biological process | regulation of GTPase activity |
GO_0042753 | Biological process | positive regulation of circadian rhythm |
GO_0021549 | Biological process | cerebellum development |
GO_1904753 | Biological process | negative regulation of vascular associated smooth muscle cell migration |
GO_0006468 | Biological process | protein phosphorylation |
GO_0016358 | Biological process | dendrite development |
GO_0007286 | Biological process | spermatid development |
GO_0001669 | Cellular component | acrosomal vesicle |
GO_0005886 | Cellular component | plasma membrane |
GO_0042383 | Cellular component | sarcolemma |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005794 | Cellular component | Golgi apparatus |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0004692 | Molecular function | cGMP-dependent protein kinase activity |
GO_0106310 | Molecular function | protein serine kinase activity |
GO_0048273 | Molecular function | mitogen-activated protein kinase p38 binding |
GO_0030553 | Molecular function | cGMP binding |
GO_0005246 | Molecular function | calcium channel regulator activity |
GO_0042802 | Molecular function | identical protein binding |
GO_0004672 | Molecular function | protein kinase activity |
GO_0005524 | Molecular function | ATP binding |
GO_0005515 | Molecular function | protein binding |
Gene name | PRKG1 |
Protein name | Protein kinase cGMP-dependent 1 cGMP-dependent protein kinase (EC 2.7.11.12) cGMP-dependent protein kinase 1 (cGK 1) (cGK1) (EC 2.7.11.12) (cGMP-dependent protein kinase I) (cGKI) |
Synonyms | PRKGR1A PRKG1B PRKGR1B |
Description | FUNCTION: Serine/threonine protein kinase that acts as a key mediator of the nitric oxide (NO)/cGMP signaling pathway. GMP binding activates PRKG1, which phosphorylates serines and threonines on many cellular proteins. Numerous protein targets for PRKG1 phosphorylation are implicated in modulating cellular calcium, but the contribution of each of these targets may vary substantially among cell types. Proteins that are phosphorylated by PRKG1 regulate platelet activation and adhesion, smooth muscle contraction, cardiac function, gene expression, feedback of the NO-signaling pathway, and other processes involved in several aspects of the CNS like axon guidance, hippocampal and cerebellar learning, circadian rhythm and nociception. Smooth muscle relaxation is mediated through lowering of intracellular free calcium, by desensitization of contractile proteins to calcium, and by decrease in the contractile state of smooth muscle or in platelet activation. Regulates intracellular calcium levels via several pathways: phosphorylates IRAG1 and inhibits IP3-induced Ca(2+) release from intracellular stores, phosphorylation of KCNMA1 (BKCa) channels decreases intracellular Ca(2+) levels, which leads to increased opening of this channel. PRKG1 phosphorylates the canonical transient receptor potential channel (TRPC) family which inactivates the associated inward calcium current. Another mode of action of NO/cGMP/PKGI signaling involves PKGI-mediated inactivation of the Ras homolog gene family member A (RhoA). Phosphorylation of RHOA by PRKG1 blocks the action of this protein in myriad processes: regulation of RHOA translocation; decreasing contraction; controlling vesicle trafficking, reduction of myosin light chain phosphorylation resulting in vasorelaxation. Activation of PRKG1 by NO signaling alters also gene expression in a number of tissues. In smooth muscle cells, increased cGMP and PRKG1 activity influence expression of smooth muscle-specific contractile proteins, levels of proteins in the NO/cGMP signaling pathway, down-regulation of the matrix proteins osteopontin and thrombospondin-1 to limit smooth muscle cell migration and phenotype. Regulates vasodilator-stimulated phosphoprotein (VASP) functions in platelets and smooth muscle. . |
Accessions | A0A2R8YH74 A0A2R8Y507 B1ALS0 ENST00000373976.9 Q13976 ENST00000645324.1 ENST00000643704.1 ENST00000672084.1 A0A2R8YE50 ENST00000401604.8 [Q13976-1] ENST00000373980.11 [Q13976-2] ENST00000643582.1 A0A5F9ZGW0 |